Ercanetide
Ercanetide (NNZ 2591) is a synthetic analogue of a small peptide of cyclic glycine proline (cGP) . Ercanetide shows orally active and cross the blood-brain barrier. Ercanetide shows neuroprotective after ischemic brain injury. NNZ 2591 improves motor function in a rat model of Parkinson's disease. Ercanetide has the potential for the research of ischemic brain injury and angelman syndrome[1][2][3].
Product Specifications
CAS Number
847952-38-9
Product Name Alternative
NNZ-2591
UNSPSC
12352209
Target
Biochemical Assay Reagents
Type
Peptides
Related Pathways
Others
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/nnz-2591.html
Purity
99.98
Solubility
DMSO : 18.75 mg/mL (ultrasonic)
Smiles
C=CC[C@@]12N(CCC2)C(CNC1=O)=O
Molecular Formula
C10H14N2O2
Molecular Weight
194.23
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
TGFBI (Transforming Growth Factor Beta Induced Protein, CSD, CDB1, CDG2, CSD1, CSD2, CSD3, EBMD, LCD1, BIGH3, CDGG1) (MaxLight 405)
TGFBI (Transforming Growth Factor Beta Induced Protein, CSD, CDB1, CDG2, CSD1, CSD2, CSD3, EBMD, LCD1, BIGH3, CDGG1) (MaxLight 405)
Lentiviral human BIRC6 shRNA (UAS) - Lentiviral human BIRC6 shRNA (UAS, GFP) plasmid
ASF1B (Anti-silencing Function Protein 1 Homolog B, CIA-II) (HRP).
ASF1B (Anti-silencing Function Protein 1 Homolog B, CIA-II) (HRP).